Share this article on:

Prolonged VV ECMO (265 Days) for ARDS without Technical Complications

Wiktor, Arek J. MD; Haft, Jonathan W. MD; Bartlett, Robert H. MD; Park, Pauline K. MD; Raghavendran, Krishnan MD; Napolitano, Lena M. MD

doi: 10.1097/MAT.0000000000000181
Brief Communications

The usual duration of extracorporeal membrane oxygenation (ECMO) in patients with severe acute respiratory distress syndrome is 7–10 days. Prolonged duration ECMO (defined as greater than 14 days) is increasingly being documented with native lung recovery or as a bridge to lung transplantation. We report a case of prolonged duration ECMO (6,364 hours, 265 days) requiring no complete circuit exchange. As critical care improves, prolonged ECMO will continue to pose unique technological and ethical challenges that test our expectations of this treatment modality. There is a critical need for diagnostic modalities to provide objective assessment of native lung recovery in patients requiring prolonged duration ECMO.

From the Department of Surgery, University of Michigan, Ann Arbor, MI 48109-5033.

Disclosure: The authors have no conflicts of interest to report.

Correspondence: Lena M. Napolitano MD, FACS, FCCP, FCCM, Professor of Surgery, Division Chief, Acute Care Surgery, Trauma, Burns, Critical Care, Emergency Surgery, Director, Trauma and Surgical Critical Care, Associate Chair, Department of Surgery, University of Michigan Health System, Room 1C340-UH, University Hospital, 1500 East Medical Drive, SPC 5033, Ann Arbor, MI 48109-5033. E-mail: lenan@umich.edu

A 40 year old woman with no past medical history presented with 1 week of upper respiratory symptoms and viral prodrome (extremity swelling, myalgias, arthralgias). Left thoracoscopic lung biopsy confirmed cryptogenic organizing pneumonia but was complicated by left bronchopleural fistula and worsening severe hypoxemia/hypercarbia (arterial blood gas (ABG), 7.34; pCO2, 74; paO2, 44) despite rescue strategies (inhaled nitric oxide, prone positioning) and systemic corticosteroids. She was transferred to our institution and required emergent veno-venous extracorporeal membrane oxygenation (VV-ECMO) for respiratory failure (right femoral 28Fr Avalon cannula, right internal jugular vein [IJ] 23Fr Biomedicus cannula) with 2 Quadrox-ID adult oxygenators and Levitronix Centrimag device. Initial ECMO settings were sweep 2 L/min, flow 4.6 L/min, 3,500 RPM, heparin infusion (goal activated partial thrombosis time (aPTT) 40–50 sec), target hemoglobin 10 mg/dl, and platelets greater than 100,000. The ECMONet score before ECMO cannulation was 4 (cutoff 4.5 for mortality risk prediction).1 Tracheostomy was performed 8 days later.

To facilitate early mobility and reconditioning for possible lung transplantation, the right IJ catheter was exchanged for a bicaval dual-lumen Avalon cannula2 on ECMO day 35 (827 hours). Transient bi-femoral ECMO was initiated via a new left femoral 23Fr Biomedicus cannula which facilitated guidewire exchange via the existing right IJ 23Fr single lumen cannula to a 27Fr Avalon ECMO cannula (flow 3.5–4.0 L/min).

The patient remained neurologically fully intact with no evidence of hypoxic injury. Given her age and lack of pre-existing comorbidities, the patient and family requested continuation of all critical care support. She was able to tolerate moderate exercise with bicycle reconditioning. Chest computed tomography scans confirmed decreasing diffuse lung parenchymal consolidation consistent with resolving acute respiratory distress syndrome. Transient pulmonary hypertension (estimated right ventricle systolic pressure 73 mm Hg) required medical management; follow-up transthoracic echocardiogram showed an ejection fraction greater than 70% with hyperdynamic left ventricle, mild-to-moderate tricuspid regurgitation, right ventricular enlargement with moderately decreased right ventricular systolic function, and right ventricular systolic pressure of 37 mm Hg.

Serial evaluations were performed by the multidisciplinary lung transplant team for possible lung transplantation,3,4 but she was not deemed a transplant candidate due to high panel reactive antibody (PRA) (93%) and possible pulmonary infection; desensitization therapy was also considered.5 Infectious complications included enterococcus bacteremia and fungemia (Candida parapsilosis/glabrata); however, bronchoscopic alveolar lavage cultures demonstrated only mixed oral flora, and peripheral/ECMO circuit blood cultures were negative. No prophylactic antimicrobials were used.

Although oxygenation improved, refractory hypercapnia persisted. Additional discussions were held with the patient/family regarding medical futility, and trials off ECMO were started on ECMO day 240 (5,772 hours). Increasing respiratory acidosis remained the limiting factor to ECMO independence. The patient was trialed off VV-ECMO on day 260 (6,244 hours), and remained off support for 5 days. Decannulation was performed on ECMO day 265 (6,364 hours). She died 4 days later due to pulseless electrical activity (PEA) arrest due to severe hypercapnia and respiratory acidosis. Autopsy confirmed densely fibrotic lungs with multiple pneumatoceles and sequelae of severe acute respiratory distress syndrome.

No circuit or cannula complications occurred during prolonged ECMO. Both oxygenators were exchanged twice, on ECMO days 105 (2,516 hours) and 175 (4,188 hours) due to decreased flows and poor oxygenation gradients due to clot burden. One bigger better bladder exchange was required on ECMO day 90 (2,149 hours). All component exchanges occurred without complication. Despite transitioning to the Avalon cannula and the prolonged duration of ECMO, no complete circuit exchange was ever required (Figure 1; Table 1). No prior report, to the best of our knowledge, has documented such prolonged use of ECMO support with a single bicaval cannula. The cannula site (right IJ) was managed with purse-string sutures at the insertion site and stabilizing sutures superior to this, chlorhexidine-alcohol cleansing, dry gauze dressing, and coban self-adherent wrap around the forehead. No infection at the cannula insertion site occurred.

Figure 1

Figure 1

Table 1

Table 1

This case demonstrates that current technological advances in ECMO circuit safety and simplicity6 can result in prolonged ECMO support for respiratory failure without technical complications. This case highlights the challenges encountered with prolonged ECMO support in a patient who initially had evidence of partial native lung recovery, but failed to demonstrate further improvement. Transitioning patients to the Avalon cannula to improve early mobility7,8 is one strategy to optimize recovery in prolonged ECMO.9

Prolonged ECMO poses unique ethical issues in patients who are not lung transplant candidates. We currently lack optimal diagnostic modalities for critical assessment of native lung recovery. In patients supported by left ventricular assist devices for cardiac failure, assessment of myocardial viability and native cardiac structure/function is feasible using noninvasive testing10 although it does not always equate with clinical recovery.11 Future studies are warranted to determine reversibility of lung injury.

Back to Top | Article Outline

REFERENCES

1. Pappalardo F, Pieri M, Greco T, et al.Italian ECMOnet. Predicting mortality risk in patients undergoing venovenous ECMO for ARDS due to influenza A (H1N1) pneumonia: The ECMOnet score. Intensive Care Med. 2013;39:275–281
2. Teman NR, Haft JW, Napolitano LM. Optimal endovascular methods for placement of bicaval dual-lumen cannulae for venovenous extracorporeal membrane oxygenation. ASAIO J. 2013;59:442–447
3. Diaz-Guzman E, Hoopes CW, Zwischenberger JB. The evolution of extracorporeal life support as a bridge to lung transplantation. ASAIO J. 2013;59:3–10
4. Venado A, Hoopes CW, Diaz-Guzman E. Prolonged extracorporeal membrane oxygenation use as a bridge to lung transplantation: It is time for a national registry. Chest. 2014;145:184–185
5. Snyder LD, Gray AL, Reynolds JM, et al. Antibody desensitization therapy in highly sensitized lung transplant candidates. Am J Transplant. 2014;14:849–856
6. Bartlett RH, Gattinoni L. Current status of extracorporeal life support (ECMO) for cardiopulmonary failure. Minerva Anestesiol. 2010;76:534–540
7. Morris PE, Griffin L, Berry M, et al. Receiving early mobility during an intensive care unit admission is a predictor of improved outcomes in acute respiratory failure. Am J Med Sci. 2011;341:373–377
8. Abrams D, Javidfar J, Farrand E, et al. Early mobilization of patients receiving extracorporeal membrane oxygenation: A retrospective cohort study. Crit Care. 2014;18:R38
9. Rosenberg AA, Haft JW, Bartlett R, et al. Prolonged duration ECMO for ARDS: Futility, native lung recovery, or transplantation? ASAIO J. 2013;59:642–650
10. Gupta DK, Skali H, Rivero J, et al. Assessment of myocardial viability and left ventricular function in patients supported by a left ventricular assist device. J Heart Lung Transplant. 2014;33:372–381
11. Birks EJ. Molecular changes after left ventricular assist device support for heart failure. Circ Res. 2013;113:777–791
Keywords:

extracorporeal membrane oxygenation; acute respiratory distress syndrome; circuit exchange; futility; prolonged; lung recovery

Copyright © 2015 by the American Society for Artificial Internal Organs